<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-124587</identifier>
<setSpec>0210-5705</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">HBeAg-positive chronic hepatitis B treatment with oral antiviral agents: Experience and results in clinical practice</dc:title>
<dc:description xml:lang="en">Introduction: Due to globalization and migratory movements, HBeAg+ chronic hepatitis B isbecoming increasingly important in Spain. Objective: To analyze the epidemiological features, progression, and treatment response to oral antiviral agents (OA) in HBeAg+ chronic hepatitis B patients in our area. Material and methods: We analyzed 436 patients with chronic hepatitis B infection followed up at the Ramón y Cajal Hospital from 1990 to June 2012. Results: Sixty-&amp;#64257;ve patients (14.9%) had HBeAg+ chronic hepatitis B. Seven patients in the immunotolerant phase were not treated, while the remaining 58 received treatment. Four patients were excluded: two due to severe acute hepatitis, one due to hepatitis C virus coinfection and another because of a Delta virus coinfection. Of the remaining 54 patients, 19 received interferon with or without OA, and 35 received only OA. Two patients treated for less than 1 month were not included in the analysis. The analysis was &amp;#64257;nally performed in 33 patients. The mean duration of treatment was 46.81 months (6-138). Lamivudine was the most frequently prescribed drug (39.39%) followed by tenofovir (24.24%) and entecavir (21.21%). The mean age was 42.08 ± 14 years and 75.75% (25/33) of the patients were male. Nineteen of 33 patients (57.57%) achieved seroconversion to anti-HBe, and 27.27% (9/33) showed clearance (..) (AU)</dc:description>
<dc:creator>Maroto-Castellanos, María Teresa</dc:creator>
<dc:creator>Mateos-Lindemann, María Luisa</dc:creator>
<dc:creator>García-Sánchez, Concepción</dc:creator>
<dc:creator>Moreira Vicente, Víctor F</dc:creator>
<dc:creator>García-Alonso, Francisco Javier</dc:creator>
<dc:creator>Martín-Mateos, Rosa María</dc:creator>
<dc:creator>Téllez-Villajos, Luis</dc:creator>
<dc:creator>Albillos, Agustín</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Introducción: La globalización y los movimientos migratorios hacen que la hepatitis crónica B Age+ (HCBe+) cobre cada día mayor relevancia en nuestro entorno. Objetivo Analizar las características epidemiológicas, evolución y respuesta al tratamiento con antivirales orales (AO) de los pacientes con HCBe+.Material y métodosSe analizaron 436 casos de infección crónica por el virus de la hepatitis B atendidos en el Hospital Universitario Ramón y Cajal desde 1990 hasta junio del 2012.ResultadosSesenta y cinco (14,9%) presentaban HCBe+. Siete pacientes en fase de tolerancia inmune no fueron tratados; los 58 restantes, sí. Fueron excluidos 4: 2 hepatitis agudas graves, una coinfección por VHC y otro por virus Delta. De los 54 restantes, 19 recibieron interferón con o sin AO y 35 solo (..) (AU)</dc:description>
<dc:source>Gastroenterol Hepatol;37(5): 280-288, mayo 2014. ilus, tab</dc:source>
<dc:identifier>ibc-124587</dc:identifier>
<dc:title xml:lang="es">Tratamiento de la hepatitis crónica B antígeno e positiva con antivirales orales: experiencia y resultados en la práctica clínica</dc:title>
<dc:subject>^d29611</dc:subject>
<dc:subject>^d33343^s22057</dc:subject>
<dc:subject>^d^s22080</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d28571</dc:subject>
<dc:subject>^d1002^s22073</dc:subject>
<dc:subject>^d32732^s22001</dc:subject>
<dc:subject>^d4716^s22083</dc:subject>
<dc:type>article</dc:type>
<dc:date>201405</dc:date>
</metadata>
</record>
</ibecs-document>
